Skip to content
The Nexus
DossierENTITY

Linda Shu

Coverage of Linda Shu in the Nexus archive.

Earliest in view: Jul 2 · 11:00 UTCMost recent: Jul 2 · 11:00 UTC
Co-mentioned in this coverage
Chinaplace2United Statesplace2HSBCorganization2AI-driven drug-design firmstopic1biotech firmsorganization1pharmaceutical companiesorganization1AI drug-designtopic1Biotech companiestopic1
Recent coverage
  • BUSINESSJul 2 · 11:00 UTCSCMP CHINA
    China AI drug-design deals swell as US scrutiny mounts

    China's AI-driven drug-design firms are expanding globally through cross-border dealmaking, with out-licensing deals to major pharmaceutical companies reaching $75 billion in the first five months of 2026, up from zero before 2020. This growth occurs despite increasing US scrutiny of Chinese biotech firms.

  • BUSINESSJul 2 · 11:00 UTCSCMP WORLD
    China AI drug-design deals swell as US scrutiny mounts

    Chinese AI-driven drug-design firms are securing global deals despite US scrutiny, with out-licensing deals reaching $75 billion in the first five months of 2026, up from zero before 2020.

Linda Shu · Dossier · The Nexus